SECsense Logo

Anebulo Pharmaceuticals 8-K Report: Key Updates & Insights for Investors

$ANEB
Form 8-K
Filed on: 2024-12-23
Source
Anebulo Pharmaceuticals 8-K Report: Key Updates & Insights for Investors

Based on the provided section of the financial report, here are the key insights and important information extracted:

  1. Entity Information:
  • Company Name: Anebulo Pharmaceuticals, Inc.
  • CIK Number: 0001815974
  • IRS Employer Identification Number (EIN): 85-1170950
  • Address: 1017 Ranch Road 620 South, Suite 107, Lakeway, TX 78734
  • Contact Number: (512) 598-0931
  1. Filing Information:
  • Filing Type: 8-K (Current Report)
  • Filing Date: December 22, 2024
  • SEC File Number: 001-40388
  1. Stock Information:
  • Stock Ticker Symbol: ANEB
  • Exchange: NASDAQ
  • Common Stock Par Value: $0.001 per share
  1. Reporting Context:
  • Reporting Date: The report is dated as of December 22, 2024.
  • Financial Units: The financial data is reported in USD (United States Dollar) and shares.
  1. XBRL Context:
  • The document is formatted using XBRL (eXtensible Business Reporting Language), which is commonly used for SEC filings to facilitate data analysis and comparison.

Summary Insights:

  • Anebulo Pharmaceuticals, Inc. is a publicly traded company listed on NASDAQ under the ticker symbol ANEB.
  • The report is a current filing (Form 8-K), indicating that it contains significant events or changes that may be of interest to shareholders and investors.
  • The filing provides essential information about the company's stock and its financial reporting date, ensuring stakeholders are informed about the latest updates.

This information would be critical for investors, analysts, and other stakeholders to assess the company's current status and make informed decisions.